(RTTNews) - Stereotaxis Inc. (STXS), a surgical robotics company, on Thursday announced the acquisition of Robocath, an established robotics company for interventions in cardiology and neurointerventions.
The companies plan to pool resources in developing next-generation robotic solutions for electrophysiology, interventional cardiology, and endovascular procedures.
Stereotaxis previously announced the acquisition in April 2026 via a share sale agreement worth approximately $20 million in cash and common stock.
With the agreement, the company also gains Robocath's proprietary R-One technology, which has shown a 98% technical procedure success with no major cardiovascular events reported. The technique has received clearance in Europe and China.
STXS is currently trading at $1.76, down 2.22%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
